iShares Biotechnology ETF
865 hedge funds and large institutions have $5.2B invested in iShares Biotechnology ETF in 2023 Q4 according to their latest regulatory filings, with 122 funds opening new positions, 177 increasing their positions, 372 reducing their positions, and 73 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
865
Holders Change
+39
Holders Change %
+4.72%
% of All Funds
12.68%
Holding in Top 10
10
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+11.11%
% of All Funds
0.15%
New
122
Increased
177
Reduced
372
Closed
73
Calls
$353M
Puts
$1.42B
Net Calls
-$1.07B
Net Calls Change
-$469M
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$300M |
| 2 |
MMEA
Main Management ETF Advisors
San Francisco,
California
|
+$74.1M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$29.6M |
| 4 |
JPMorgan Chase & Co
New York
|
+$25.1M |
| 5 |
JHU
Johns Hopkins University
Baltimore,
Maryland
|
+$21.9M |
Top Sellers
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$170M |
| 2 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$44.2M |
| 3 |
MMA
Miracle Mile Advisors
Los Angeles,
California
|
-$40.9M |
| 4 |
Goldman Sachs
New York
|
-$33M |
| 5 |
Jane Street
New York
|
-$26.4M |